We scan new podcasts and send you the top 5 insights daily.
Engineers often finalize a bare metal scaffold before addressing its covering, expecting the membrane to not affect radial strength or crimp profile. However, a covered stent behaves as a composite material where the scaffold, polymer, and vessel properties interact and must be designed simultaneously.
Engineering teams meticulously document component details but often fail to apply the same rigor to assembly specifications. This oversight becomes a major source of failure, especially when transitioning from pilot lines to high-volume manufacturing.
In standard ePTFE sintering, two polymer layers fuse only to each other through the stent's openings rather than adhering to the metal struts. Because this creates only a mechanical capture instead of a direct chemical bond, voids can develop near the struts during loading and deployment.
While PEBAX isn't a top-tier polymer for many standard applications, its use in catheters is strategic. The primary reason for its selection is its unique ability to bond effectively to both softer and stiffer materials, which is essential for creating catheters with varying flexibility along their length.
Thermal sintering of ePTFE requires heating assemblies between 340°C and 360°C to encapsulate the stent. Exposing a pre-shaped nitinol frame to these elevated process temperatures during covering risks altering the shape setting and mechanical training of the underlying alloy.
Replacing manual suturing with polymer lamination requires fabrics with sufficient elongation, such as knitted textiles, so the material stretches alongside the collapsing metal frame. When using inelastic woven fabrics, the stent frame must be sewn loosely so it can slide through sutures during crimping.
The core innovation for the Cobra OS wasn't a complex discovery but the disciplined application of a known principle: miniaturizing endovascular devices always makes them safer. By focusing on shrinking the device, they inherently improved safety by reducing the size of the arterial access site.
Engineering teams often default to hand-sewn stent covers in early phases because manual suturing is readily accessible and can be performed in-house. This initial convenience biases downstream architecture, committing programs to design constraints based on early prototyping ease rather than clinical optimization.
Experts often design components in isolation, perfecting their specific 'Lego' piece. When it's time to assemble the final device, these pieces fail to fit together because a systems-level approach was missing from the start, leading to costly rework and integration challenges.
Because chronic animal studies are costly and slow, engineering teams frequently receive in vivo data very late in product development. Consequently, issues like unexpected thrombosis or density mismatches are uncovered just prior to clinical trials, forcing abrupt redesigns between product generations.
At Neuronoff, a three-year project was dedicated to ensuring their "injectrode" could be safely removed—a factor often overlooked in device design. This proactive approach prevents future complications where devices must be abandoned in a patient's body because they are too difficult to extract.